News
11-09-2011, 01:50 AM
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its ECLIPSE 2 Phase I/IIa study indicate that treatment with four weeks of the Company's investigative immune-modulator, recombinant human Interleukin-7, added to peginterferon and ribavirin in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC, induces a broad immune response associated with HCV viral clearance in genotype 1 and 4 treatment experienced patients defined as nonresponders to SOC.
More... (http://www.news-medical.net/news/20111109/Interim-data-from-Cytheris-CYT107-Phase-IIIa-combination-study-on-HCV.aspx)
More... (http://www.news-medical.net/news/20111109/Interim-data-from-Cytheris-CYT107-Phase-IIIa-combination-study-on-HCV.aspx)